Category - Feature

Feature

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Closely-held ADvantage Therapeutics is awaiting regulatory approval in Europe to proceed with a Phase 2b confirmatory clinical trial of its lead drug candidate, AD04, for the treatment of mild Alzheimer’s disease (AD).

May 16, 2023

Feature

Peptilogics lead peptide platform targeting serious joint replacement infections

Peptilogics is working to change the treatment paradigm of periprosthetic joint infection (PJI), a serious condition that can result from joint replacement surgery. The company is preparing for a registrational clinical...

May 9, 2023

Feature

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

UK based biotechnology company SynaptixBio is developing the world’s first life-saving medicine for TUBB4A leukodystrophy, a rare genetic neurodegenerative disease that affects approximately 1,600 newborn babies and...

May 2, 2023

Feature

EyePoint focused on long-lasting treatments for wet AMD and DR

EyePoint Pharmaceuticals (NASDAQ:EYPT) is advancing its lead drug candidate, EYP-1901, in two Phase 2 clinical trials as a potential six-month treatment for wet age-related macular degeneration (AMD) and a potential...

April 25, 2023

Feature

Alaunos attacking solid tumors with cutting-edge TCR-T cell therapies

Alaunos Therapeutics (NASDAQ:TCRT) is developing a library of T-cell receptor (TCR) cell therapies with the potential to revolutionize the treatment of solid tumors.

April 18, 2023

Feature

Rezolute focused on paradigm shift treating DME

Rezolute (NASDAQ:RZLT) is working on therapies targeting both ends of the spectrum of dysregulated glucose. It has now entered Phase 2 with an oral therapy to treat diabetic macular edema (DME), a big market...

April 11, 2023

Feature

KeifeRx developing oral TKIs for neurodegenerative and immune diseases

Closely-held KeifeRx is developing optimized, low dose, oral tyrosine kinase inhibitors (TKIs) for the treatment of multiple neurodegenerative and immune diseases.

April 4, 2023

Feature

BioStem Technologies harnessing perinatal tissue for regenerative therapies

Fresh from a decision by the Center for Medicare Services to establish national pricing for its VENDAJE allografts for regenerative therapies, BioStem Technologies (OTCQB:BSEM) is gearing up for a new spurt of growth.

March 28, 2023

Feature

Enveric taking new approach to mental health challenges

Enveric Biosciences (NASDAQ:ENVB) has created a library of more than 500 new chemical entities from its drug platform, including next generation psilocybin analogues for the treatment of anxiety, depression, and...

March 21, 2023

Feature

bioAffinity rolling out CyPath for early detection of lung cancer

bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.

March 14, 2023

Category - Feature

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Peptilogics lead peptide platform targeting serious joint replacement infections

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

EyePoint focused on long-lasting treatments for wet AMD and DR

Alaunos attacking solid tumors with cutting-edge TCR-T cell therapies

Rezolute focused on paradigm shift treating DME

KeifeRx developing oral TKIs for neurodegenerative and immune diseases

BioStem Technologies harnessing perinatal tissue for regenerative therapies

Enveric taking new approach to mental health challenges

bioAffinity rolling out CyPath for early detection of lung cancer

General

More